Therapeutic use of Z-521

Therapeutic use of oral sodium phosphate (Z-521) in primary hypophosphatemic rickets (familial rickets, X-linked hypophosphatemia, vitamin D-resistant rickets)

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221295

Enrollment

Registered

2010-11-02

Start date

2010-11-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary hypophosphatemic rickets

Interventions

investigational material(s) Generic name etc : Z-521 INN of investigational material : Therapeutic category code : 322 Mineral preparations Dosage and Administration for Investigational material : 30

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: subjects diagnosed as primary hypophosphatemic rickets based on familial history, genetic test or laboratory test results

Exclusion criteria

Exclusion criteria: subjects with hyperparathyroidism

Design outcomes

Primary

Measure	Time frame
serum ALP ( alkaline phosphatase ) level serum phosphate level	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026